Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Metastatic Leiomyosarcoma

NCT03420014 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT03420014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03420014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Metastatic Leiomyosarcoma
Lead sponsor
Philogen S.p.A.
Phase
Phase 2
Overall status
Unknown status
Start date
December 27, 2018
Completion date
December 31, 2025
Enrollment
114 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

leiomyosarcoma